Epitope Mapping and Binding Assessment by Solid-State NMR Provide a Way for the Development of Biologics under the Quality by Design Paradigm

Domenico Rizzo,⊥ Linda Cerofolini,⊥ Stefano Giuntini, Luisa Iozzino, Carlo Pergola, Francesca Sacco, Angelo Palmese, Enrico Ravera, Claudio Luchina,* Fabio Baroni,* and Marco Fragai*

ABSTRACT: Multispecific biologics are an emerging class of drugs, in which antibodies and/or proteins designed to bind pharmacological targets are covalently linked or expressed as fusion proteins to increase both therapeutic efficacy and safety. Epitope mapping on the target proteins provides key information to improve the affinity and also to monitor the manufacturing process and drug stability. Solid-state NMR has been here used to identify the pattern of the residues of the programmed cell death ligand 1 (PD-L1) ectodomain that are involved in the interaction with a new multispecific biological drug. This is possible because the large size and the intrinsic flexibility of the complexes are not limiting factors for solid-state NMR.

INTRODUCTION

Drug discovery is a long and costly process that has a very low success rate. Structural biology is the game-changer for the identification and optimization of new lead compounds, but the relevance of the structural information that can be gathered is causing structural biology to emerge also for the development of biotherapeutics.1,2

As defined by international guidelines, pharmaceutical development should adhere to the Quality by Design paradigm (QbD), described by ICH Q8 (R2)3 from the European Medicine Agency (EMA) as a "systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management". This important concept has revolutionized drug development by highlighting the importance of new analytical strategies based on advanced product and process knowledge. Developing a drug under the QbD paradigm not only aims at improving the quality and safety of pharmaceutical products but also at increasing the success rate by improving Critical Quality Attributes risk assessments, leading to more focused control strategies and release testing panels.

Monoclonal antibodies (mAbs) are, to date, the major class of biological drugs approved for the treatment of a large variety of pathologies, and new engineering solutions have solved most of the serious problems encountered in the therapeutic use of these proteins, improving the interactions with the effector cells, leading to less immunogenic molecules and allowing the selection of high-affinity species.4,5 Among these drugs, multispecific biologics obtained by fusing full-length antibodies, fragment antigen-binding (FAB), or other proteins together represent the next generation of biotherapeutics.6–12 This entire class of drugs can benefit from structural information obtained by investigating their complexes with the targets, for example, to reshape and optimize the interaction site.13,14

Structural information at the atomic level about the macromolecular complexes is routinely obtained using X-ray crystallography,15,16 much less so by NMR17,18 and, more recently, cryo-electron microscopy.19,20 However, the large molecular weight and the flexibility of fusion-derived biotherapeutics often prevent the structural characterization of their complexes with the targets. For instance, a large inherent flexibility makes it difficult to obtain crystals of diffraction quality or cryo-EM reconstruction. At the same time, the large molecular weight of these systems hampers a deep structural characterization by NMR in solution, although NMR is successfully used in the higher-order structure (HOS) assessment.21–29 Relevant and complementary information can be obtained from hydrogen–deuterium exchange coupled to
mass spectrometry (HDX-MS): characterization of interaction surfaces in protein complexes is one of the strengths of this technique, but complex and extensive method optimization is needed, and data interpretation is not straightforward.

Thanks to advances in the instrumentation and in sample preparation, solid-state NMR has reached sufficient maturity to start tackling systems of outstanding complexity, such as biological drugs, vaccine formulations, etc. A few years ago, a pioneering work by the group of Lewandowski reported the solid-state NMR characterization of a precipitated macromolecular complex between the first immunoglobulin binding domain of streptococcal protein G (GB1) and a full-length antibody.32 GB1 is a 6 kDa protein33 that is extensively used as a standard in solid-state NMR,67,68 and is reported to bind strongly to the crystallizable region fragment and weakly to the antigen-binding fragment of human immunoglobulin G. These results and previous studies on noncrystalline systems suggest that also very large macromolecular systems involving fusion-derived biologics can be characterized by solid-state NMR spectroscopy.34−62 One of the advantages of the noncrystalline samples, obtained by sedimentation or equivalently by rehydrating freeze-dried proteins,63 is the absence of crystalline (ordered) packing.64 Indeed, the shift perturbations due to the contacts among the different protein molecules are averaged over several poses with no energetic preferences and the hydration state of the biomolecules is closer to that present in solution.65,66 Therefore, a rehydrated freeze-dried material corresponds to an extremely concentrated solution of the protein, which is intrinsically comparable, for the scope of chemical shift mapping, to the diluted sample used for acquiring solution spectra.65

The observation of well-resolved spectra on a noncrystalline system of a small protein is not trivial: in our experience, noncrystalline samples of small proteins—including domains or fragments of therapeutic targets—can provide poor-quality solid-state NMR spectra63 that have discouraged so far the use of this strategy in the investigation of pharmaceutical relevant systems and in the development of biologics. Local structural inhomogeneity under magic angle spinning (MAS) conditions is among the possible reasons of the unsatisfactory quality of solid-state spectra recorded on noncrystalline samples of some small proteins. In the case of antibodies, however, since they usually bind a target with very high affinity by establishing an extensive network of interactions, a structural stabilization of the interacting protein is expected.

Programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) axis is one of the immune checkpoints that under healthy conditions promote self-tolerance and protect the host from autoimmunity.66 However, the PD-1/PD-L1 cascade is also used by several cancer cell lines to avoid the immune response by overexpressing the PD-L1 transmembrane protein on the surface.67,68 The ectodomain of PD-L1 is the interacting protein is expected.

Figure 1. Here, we show that the epitope mapping of this Fc-fusion protein on the PD-L1 ectodomain can be achieved by integrating solution and solid-state NMR studies and that the structural information obtained with our approach can be used to provide usable knowledge to develop a biotherapeutic under the Quality by Design paradigm (QbD).

### Methods

Expression and Purification of [U-13C, 15N] and [U-2H, 13C, 15N] PD-L1. Escherichia coli BL21 (DE3) cells were transformed with pET-21a (+) plasmid encoding PD-L1 gene (residues Ala18-Tyr134). To obtain uniformly isotopically enriched PD-L1 [13C, 15N], the cells were cultured in M9 Minimal Medium supplied with 3 g of [13C]glucose, 1.1 g of [15N]-NH₄Cl, 1 cm³ of 0.1 mg cm⁻³ solution of ampicillin, 1 cm³ of 1 mg cm⁻³ thiamine, 1 cm³ of 1 mg cm⁻³ biotin, 1 mmol dm⁻³ MgSO₄, 0.3 mmol dm⁻³ CaCl₂, grown at 310 K, until OD600 reached 0.8, then induced with 1 mmol dm⁻³ isopropyl β-D-thiogalactopyranoside. They were further grown at 310 K overnight and then harvested by centrifugation at 7500 g (JA-10 Beckman Coulter) for 15 min at 277 K.

For uniformly isotopically enriched PD-L1 [U-2H, 13C, 15N], the cells were cultured in H-2H, C-13N-enriched medium (E. coli-O2D2 rich growth media) containing 1 cm³ of 0.1 mg cm⁻³ solution of ampicillin, grown at 310 K, until OD600 reached 0.6, then induced with 1 mmol dm⁻³ isopropyl β-D-thiogalactopyranoside; all reagents were previously dissolved in 2H₂O. The cells were further grown at 310 K overnight and then harvested by centrifugation at 7500 g (JA-10 Beckman Coulter) for 15 min at 277 K.

In all instances, the pellet was suspended, first, in 50 mmol dm⁻³ Tris-HCl pH 8.0, 200 mmol dm⁻³ NaCl, 10 mmol dm⁻³ β-mercaptoethanol, and 10 mmol dm⁻³ ethylenediaminetetraacetic acid (EDTA) (50 cm³ per dm³ of culture) and sonicated for 30 ± 10 times on ice at 277 K. The suspension was centrifuged at 115,000 g (Beckman Optima LE-80K Ultracentrifuge) for 40 min and the supernatant discarded. The recovered pellet was resuspended in 50 mmol dm⁻³ Tris-HCl pH 8.0, 200 mmol dm⁻³ NaCl, 10 mmol dm⁻³ β-mercaptoethanol, 6 mol dm⁻³ guanidinium chloride (25 cm³ per dm³ of culture) and newly incubated at 277 K overnight under magnetic stirring. Again, the suspension was centrifuged at 115,000 g (Beckman Optima LE-80K Ultracentrifuge) for 40 min. The pellet was discarded, whereas the supernatant containing the denatured protein solution was diluted in a refolding buffer containing 0.1 mol dm⁻³ Tris-HCl, pH 8.5, 1 mol dm⁻³ arginine, 0.25 mmol dm⁻³ reduced glutathione, and 250 mmol dm⁻³ oxidized glutathione.32 The solution was incubated at 277 K under stirring, for 12−18 h, cleared by passing a 0.45 μm filter, and...
then dialyzed extensively against 10 mmol dm$^{-3}$ Tris, pH 8.0, 20 mmol dm$^{-3}$ NaCl. The protein solution was concentrated with an Amicon Stirred Cell and then purified by size exclusion chromatography on HiLoad Superdex 26/60 75pg (GE Healthcare) previously equilibrated in 0.1 mol dm$^{-3}$ 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 6.8 and 20 mmol dm$^{-3}$ NaCl.

**NMR Measurements.** Solution NMR experiments for backbone resonance assignment [three-dimensional (3D) HNCA, HN(CB)CA, CBCA(CO)NH, HNCO, HNCO, HN(CA)CA, HN(CA)CB(CA)NH] were performed on [U-^{13}C,^{15}N] PD-L1 samples of PD-L1 (at the concentration of 150 mmol dm$^{-3}$) in the water buffer solution where the protein was more stable [10 mmol dm$^{-3}$ Tris, pH 8, 20 mmol dm$^{-3}$ NaCl, 0.1% Na$_3$P$_4$, protease inhibitors (Roche)]. For 3D HNCA nonuniform random sampling at 64% and compressed-sensing reconstruction was used. A 3D HNCA was also recorded at a lower pH [buffer: 20 mmol dm$^{-3}$ HEPES, pH 6.8, 20 mmol dm$^{-3}$ NaCl, 0.1% Na$_3$P$_4$, protease inhibitors (Roche)] to identify a higher number of spin systems and to transfer the protein assignment to buffer conditions closer to those of the anti-PD-L1 fusion protein. All solution spectra were recorded at 298 K on Bruker Avance III and Avance NEO NMR spectrometers, operating at 1200, 950, and 900 MHz, $^1$H Larmor frequency, wide-bore probe-heads. The spectra of the free protein were, instead, acquired with bottom and top Vespel caps, Bruker Biospin. The dry samples were then rehydrated by multiple additions of Milli-Q H$_2$O until the concentrations of 2.5, 5, and 7.5 mmol dm$^{-3}$ of anti-PD-L1 fusion protein. Each addition of the anti-PD-L1 fusion protein was monitored by two-dimensional (2D) $^1$H-$^1$H SOFAST HMQC spectra. The excess of unbound PD-L1 was then purified from the complex by HiLoad Superdex 16/60 200pg gel filtration (GF) chromatography and buffer-exchanged to 1 mmol dm$^{-3}$ HEPES and 4 mmol dm$^{-3}$ NaCl. The solutions of the complexes (containing $\sim$10 mg of material) were freeze-dried and the materials used to pack 3.2 mm zirconia thin-wall rotors (open-ended, with bottom and top Vespel caps, Bruker Biospin). The dry samples were then rehydrated by multiple additions of Milli-Q H$_2$O until the resolution of the one-dimensional (1D) [$^1$H]$^{13}$C CP spectra ($\delta_1 = 70$ kHz; $\delta_2 = 42$ kHz) spectra stopped changing. Silicon plugs (courtesy of Bruker Biospin) placed below the turbine cap were used to close the rotors and preserve hydration. The complex between [U-$^3$H, $^13$C, $^{15}$N] PD-L1 and anti-PD-L1 fusion protein was subsequently transferred in a 1.3 mm zirconia rotor (Bruker Biospin).

A sample of PD-L1 in the presence of a nonbinding antibody (nb-mAb) was also prepared as reference sample. Increasing aliquots of this product [25 mg cm$^{-3}$ ($\sim$250 mmol dm$^{-3}$)] to reach the concentrations of 12.5 and 25 mmol dm$^{-3}$ nb-mAb were added to the solution of [U-$^3$H, $^13$C, $^{15}$N] PD-L1 [50 mmol dm$^{-3}$ in 100 mmol dm$^{-3}$ HEPES, 20 mmol dm$^{-3}$ NaCl, pH 6.8]. The spectra were then rehydrated at 1.3 mm rotors, and the material ($\sim$13.4 mg) used to fill thick walls 3.2 mm zirconia rotor. Also in this case, the dry material was rehydrated with Milli-Q H$_2$O and the spectra acquired.

Another control sample of [U-$^3$H, $^13$C, $^{15}$N] free PD-L1 was prepared by lyophilization in the presence of PEG, and spectra were acquired before and after rehydration, for reference to the SSNMR.

The SSNMR spectra of PD-L1 in the presence of mAbs were collected on a Bruker Avance III spectrometer operating at 800 MHz, $^1$H Larmor frequency (18.8 T, 201 MHz $^{13}$C Larmor frequency), equipped with a Bruker 3.2 mm Ei500, and Bruker 1.3 mm NCH probe-heads. The spectra of the free protein were, instead, acquired on a Bruker Avance III 850 MHz, $^1$H Larmor frequency, wide-bore spectrometer (20 T, 213.6 MHz $^{13}$C Larmor frequency), equipped with a 3.2 mm DVT MAS probe head in triple-resonance mode. The spectra were recorded at 14 and 60 kHz MAS frequencies, for the 3.2 and 1.3 mm rotors, respectively, and the sample temperature was kept at $\sim$290 K.

Standard $^{13}$C-detected SSNMR spectra [2D $^{13}$N-$^1$H NCA, $^{13}$N-$^1$H NCO, and $^{13}$C-$^1$H DARR, mixing time 50 ms] were acquired on the samples in 3.2 mm rotors, while $^1$H-detected SSNMR spectra [2D $^{13}$N-$^1$H CP-heteronuclear single quantum coherence (HSQC), 3D (H)CANH, 3D (H)CONH, and the $^1$H-$^{13}$C 2D plane of 3D (H)(CA)CB(CA)NH] were acquired on the sample in 1.3 mm rotor, using the pulse sequences reported in the literature. Experimental details are reported in Tables S1 and S2. For comparison, two-dimensional carbon-detected solution NMR spectra [$^{15}$C,$^{15}$N CON (best-version), CACO and CBCABC] were acquired using a Bruker AVANCE NEO 700 spectrometer equipped with a triple-resonance Cryo-Probe optimized for $^{13}$C-direct detection, on a sample of free PD-L1 (50 mmol dm$^{-3}$ in 100 mmol dm$^{-3}$ MES, pH 6.8, 20 mmol dm$^{-3}$ NaCl).

All of the spectra were processed with the Bruker TopSpin 3.2 software and analyzed with the program CARA.

### RESULTS

First, we proceeded to an extensive NMR characterization of the isolated PD-L1 ectodomain in solution and in the solid state to evaluate the quality of the spectra and to perform the backbone assignment. Isotopically enriched samples of PD-L1 ectodomain can be expressed in E. coli, while the labeling of full-length antibodies is still extremely challenging, although not impossible in principle.

**NMR Characterization of the Isolated PD-L1 Ectodomain.** The 2D $^1$H-$^{15}$N HSQC of free PD-L1 in solution shows sharp and well-resolved signals, as expected for a structured low-molecular-weight protein ($\sim$13.5 kDa). The backbone assignment of free PD-L1 was obtained from the analysis of triple-resonance spectra acquired on samples of [U-$^{13}$C, $^{15}$N] PD-L1 in solution. All residues but the first three and Asp-61 could be assigned on the spectra (percentage of assignment 97%, Figure 2). In total, 114 signals could be identified and assigned for the free protein in solution. This is, to the best of our knowledge, the only available assignment of PD-L1. The assignment has been deposited on the bmrbr under the accession code $1169$.

Then, the isolated PD-L1 ectodomain was freeze-dried and the sample was analyzed by SSNMR. As expected for a small protein, the 1D [$^1$H]$^{13}$C CP spectrum of the dry material displays broad signals (Figure S1). Also the controlled

![Figure 2](image-url)
hydration of the material\textsuperscript{41,42} did not improve the quality and resolution of the spectra in the solid state (Figures S1 and S2).

**NMR Analysis of PD-L1 in the Presence of the Anti-PD-L1 Fusion Protein.** Samples of the PD-L1/anti-PD-L1 fusion protein complex were prepared by adding a solution of the product to solutions of the isotopically enriched PD-L1, and the titration was monitored by NMR. The addition of the anti-PD-L1 fusion protein to the solution of [U-13C, 15N] PD-L1 caused a global decrease in the intensity of the target protein’s signals in the 1D 1H and 2D 1H-15N SOFAST HMQC NMR spectra (Figures S3 and S4). This effect is due to the severe broadening of resonances resulting from the increase of the reorientation correlation time experienced by PD-L1, upon binding to the fusion protein.

Substoichiometric concentrations of the anti-PD-L1 drug were added to the PD-L1 solutions. The large PD-L1/anti-PD-L1 fusion protein complex was then purified from the residual free PD-L1 protein by gel filtration (GF) chromatography and characterized by solution NMR. Only a few signals (Gln/Asn side chains and the C-terminal H\textsubscript{N}), corresponding to atoms that preserve internal mobility after binding to the anti-PD-L1 fusion protein, were observed in the 2D 1H-15N SOFAST HMQC NMR spectrum acquired after GF (Figure S5), while signals of the free PD-L1 protein were completely disappeared.

Then, the PD-L1/anti-PD-L1 fusion protein complex was freeze-dried and analyzed by SSNMR. The 1D \{1H\}13CP SSNMR spectra of freeze-dried [U-13C, 15N] PD-L1 in complex with the anti-PD-L1 fusion protein (black, A) and in the presence of the nonbinding mAb (red, B). The spectra were recorded on the dried materials and after the addition of increasing amounts of Milli-Q H\textsubscript{2}O. Spectra were acquired on a spectrometer operating at 800 MHz (1H Larmor frequency) with a MAS of 14 kHz and a temperature of ~290 K.

Substoichiometric concentrations of the anti-PD-L1 drug were added to the PD-L1 solutions. The large PD-L1/anti-PD-L1 fusion protein complex was then purified from the residual free PD-L1 protein by gel filtration (GF) chromatography and characterized by solution NMR. Only a few signals (Gln/Asn side chains and the C-terminal H\textsubscript{N}), corresponding to atoms that preserve internal mobility after binding to the anti-PD-L1 fusion protein, were observed in the 2D 1H-15N SOFAST HMQC NMR spectrum acquired after GF (Figure S5), while signals of the free PD-L1 protein were completely disappeared.

Then, the PD-L1/anti-PD-L1 fusion protein complex was freeze-dried and analyzed by SSNMR. The 1D \{1H\}13CP spectrum collected on the freeze-dried sample was of poor quality. However, the stepwise hydration of the material leads to a significant improvement in quality and resolution of the spectrum (Figure 3A).

Hetero- and homonuclear correlation spectra were recorded on the rehydrated sample (Figure S6) and used for resonance assignment. The assignment of the 2D 15N 13C NCA spectrum (Figure 4) was obtained starting from the data collected in solution on the isolated PD-L1 and complemented by the analysis of the 2D 15N 13C NCO and 13C-13C DARR (Figure 5A) spectra of the complex which allowed us, at the same time, to obtain side-chain assignments. First, the assignment of free PD-L1 in solution was superimposed on the 2D 15N 13C NCA spectrum (Figure S7A,B). The assignment was then matched to the closest signals in the spectrum by identifying the C\textalpha{} frequencies of the neighboring signals also in the 2D 13C-13C DARR spectrum (Figure S7C). The pattern of carbon resonances correlated to the C\textalpha{} frequencies in the 2D 15N 13C DARR spectrum allowed us to identify the spin systems characteristic of each residue type and distinguish among possible ambiguities. The resolution of 2D 15N 13C NCO was lower with respect to the other spectra; however, some signals in the 2D 15N 13C NCO were helpful in confirming the 15N chemical shift values of some residues obtained from the 2D 15N 13C NCA spectrum.

Finally, a total of 99 spin systems could be identified and assigned in 13C-detected spectra. Interestingly, in addition to...
the three signals missing in solution NMR spectra, the signals of other residues located in flexible loops of PD-L1 (K25, L48, Q66, G70, L74-V76, K89, M115, G120, A132-Y134) are missing in the SSNMR spectra of the complex.

To improve the assignment of the resonances and the quality of the chemical shift mapping, a set of 1H-detected spectra was also acquired on a sample of [U-2H, 13C, 15N] PD-L1 in complex with the anti-PD-L1 fusion protein, prepared under the same experimental conditions of the previously described complex ([U-13C, 15N] PD-L1/anti-PD-L1 drug). The sample was then transferred in a 1.3 mm rotor. The 2D 15N-1H (H)NH CP-HSQC spectrum of the PD-L1/anti-PD-L1 fusion protein complex is of high quality (Figure 6). Also in this case, the assignment of the SSNMR spectrum was obtained starting from the available assignment of the free protein in solution and confirmed by the analysis of 3D spectra [(H)CANH, (H)CONH, 2D 13C-1H plane of (H)(CA)-CBNH]. Also in the 1H-detected spectra, some signals of residues belonging to flexible loops of PD-L1 (K41, K46, M59-D61, Q66, G70, L74-V76, Q83, L106, Y134) are missing. Summarizing, a total of 99 spin systems could be identified and assigned also in the 1H-detected spectra. Interestingly, in the solid state, some signals could be identified in the 13C-detected spectra, while others in the 1H-detected spectra.

Chemical Shift Perturbation (CSP) Can Map the Binding Regions of PD-L1. The availability of protein assignment for the isolated PD-L1 ectodomain in solution and for the same protein in complex with the anti-PD-L1 fusion protein in the solid state allows for the analysis of the chemical shift perturbation (CSP). The CSP of 13Cα/15N and 1H/15N resonances was calculated from the assignment of 13C- and 1H-detected SSNMR spectra, respectively, using the assignment of the isolated [U-2H, 13C, 15N] PD-L1 obtained in solution as reference. Although all residues experience a chemical shift variation moving from solution to solid-state experiments,34 those experiencing the largest chemical shift variations (Q47, E58, E60, I65, E72, Q77, H78, Q83, A93, C114, 1116, Y118, and Y123 according to 13Cα/15N chemical shift values; M36, C40, V44, I64, I65, F67, V68, Q77, H78, S80, D108, G110, C114, I116, Y118, D122, R125, and I126 according to 1H/15N chemical shift values) are located on PD-L1 β-sheets and form a large interaction surface (Figure 7).

The CSP values were also analyzed using different thresholds obtained from the iterative procedure proposed by Schumann and co-workers.96 Interestingly, this analysis showed that residues below the new calculated threshold are located in regions noninteracting with the anti-PDL-1 fusion protein (see the Supporting Information for more details, Figure S8).

Comment about Spectral Quality. To confirm that the observed improvement in quality of the solid-state spectra of PD-L1 was due to its binding to the anti-PD-L1 fusion protein, the target was titrated with a noninteracting monoclonal antibody (nb-mAb). As expected, also at high concentrations (PD-L1: nb-mAb, 1:0.5 molar ratio, Figure S9), this antibody does not affect the signals of PD-L1 in a 2D 1H-15N SOFAST
HMQC NMR spectrum. Then, the PD-L1/nb-mAb mixture was freeze-dried and analyzed by SSNMR in a 3.2 mm rotor. The experiments recorded on the sample show that in the presence of the nonbinding mAb, the stepwise rehydration does not improve sizably the quality and resolution of the solid-state spectra (Figures 3B and 5B). However, in some regions of this DARR spectrum, the signals are sufficiently resolved to be assigned and compared with those present in the 2D DARR spectrum recorded on the PD-L1/anti-PD-L1 fusion protein complex (Figure 8). The analysis of the two spectra allowed us to evaluate the occurrence of a meaningful chemical shift perturbation for some signals. Most of the signals experiencing the largest shift are indeed located on PD-L1 β-sheets that form the binding surface for anti-PD-L1 fusion protein. Conversely, the signals experiencing negligible effects are located on the opposite face of the PD-L1 protein.

DISCUSSION

The last advances in antibody engineering have led to the development of complex fused biologics with multispecific activity and increased structural complexity. Understanding such a structural complexity and how it impacts the function of...
A biotherapeutic is, on the one hand, not a trivial task, but, on the other hand, it is of paramount importance during drug development because it is strictly linked to the QbD concept. Indeed, detailed product knowledge is instrumental to the production of safer and more effective drugs and to improve process control strategies.

The epitope mapping on a target can provide the structural information needed to understand the mechanism of action of biologics by supporting structure−activity relationship (SAR) studies, that are critical during pharmaceutical development. SAR can indeed be used to explain the different ways in which a ligand interacts with a receptor: this, in turn, can be used to optimize the physicochemical and functional properties of a biotherapeutic (e.g., solubility, potency, pharmacokinetics, etc.) and can support the design of mutants with larger interacting surfaces and affinities or capable of binding mutated targets.

The results here reported prove that a detailed characterization of the binding to the target of very large and flexible biologics can be achieved by integrating solution and solid-state NMR experiments. The epitope mapping approach used in this study can be applied to other molecules and can be used to understand the structural characteristics of the proteins involved in the binding process.

Overall, this approach opens new ways to monitor HOS during pharmaceutical development, allowing us to focus on the structural alterations that may affect target recognition and binding affinity, thus linking HOS assessment to the drug mechanism of action.
The experimental protocol used here to prepare the sample is simple and every step is easily controlled. The methodology does not require the isotopic enrichment of the biological drug, which is usually expressed in eukaryotic cells and where the labeling is highly expensive, although feasible. Conversely, targets can often be obtained in E. coli expression system where the labeling is easy, inexpensive, and with high yields.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/jacs.2c03232.

1D \( ^1\)H\(^{13}\)C, 2D \( ^{13}\)C\(^{-13}\)C, and 2D \( ^{15}\)N\(^{13}\)C solid-state NMR spectra; 2D \( ^1\)H\(^{15}\)N solution NMR spectra; details of assignment and CSP; acquisition parameters for SSNMR spectra; and assignment tables (PDF)

AUTHOR INFORMATION

Corresponding Authors

Claudio Luchinat — Magnetic Resonance Center (CERM), University of Florence, 50019 Sesto Fiorentino, Italy; Department of Chemistry “Ugo Schiff”, University of Florence, 50019 Sesto Fiorentino, Italy; Consorzio Interuniversitario Risonanze Magnetiche di Metalloproteine (CIRMMP), 50019 Sesto Fiorentino, Italy; Email: luchinat@cerm.uni.it

Marco Fragai — Analytical Development Biotech Department, Merck Serono S.p.a, 00012 Guidonia, RM, Italy; Email: fabio.baroni@merckgroup.com

Enrico Ravera — Magnetic Resonance Center (CERM), University of Florence, 50019 Sesto Fiorentino, Italy; Department of Chemistry “Ugo Schiff”, University of Florence, 50019 Sesto Fiorentino, Italy; Consorzio Interuniversitario Risonanze Magnetiche di Metalloproteine (CIRMMP), 50019 Sesto Fiorentino, Italy; Email: ravera@cerm.uni.it

Notes

The authors declare the following competing financial interest(s): L.I., C.P., A.P., and F.B. were employees of Merck Serono S.p.a, Guidonia, RM, Italy, an affiliate of Merck KGaA, at the date of the analyses. This research was performed using as case study sample a product in development by Merck KGaA. While Merck KGaA has filed for patent protection regarding the product in development, the technology described in this manuscript is independent from this product of Merck KGaA. No patents or patent applications have been filed for the technology described in this manuscript.

NMR assignment in solution of PD-L1 ectodomain (residues Ala18-Tyr134) generated during the current study is available in the BMRB database under the accession code: 51169. The raw data are available at https://zenodo.org under the DOI: 10.5281/zenodo.6363169.

ACKNOWLEDGMENTS

This work was supported by Regione Toscana (CERM-IT and BioEnable), the Italian Ministero dell'Istruzione, dell'Universita' e della Ricerca through PRIN 2017A2KEPL, the “Progetto Dipartimenti di Eccellenza 2018-2022” to the Department of Chemistry “Ugo Schiff” of the University of Florence, the Recombinant Proteins JOYNLAB laboratory, and the project FISR2021_SYLCOV. The authors acknowledge the support and the use of resources of Instruct-ERIC, a landmark ESFRI project, and specifically the CIRM/CIRMMP Italy center. They also acknowledge H2020-INFRAIA iNEXT-Discovery—Structural Biology Research Infrastructures for Translational Research and Discovery (contract no. 871037), EOSC-Life “Providing an open collaborative space for digital biology in Europe” (H2020, contract no. 824087), “Glytunes” Marie Składowska-Curie Action (MSCA) Innovative Training Networks (ITN) H2020-MSCA-ITN-2020 (contract no. 956758), and PANACEA “A Pan-European Solid-State NMR Infrastructure for Chemistry-Enabling Access”, (H2020, contract n. 101008500101008500). The authors acknowledge also Mestrelab Research for providing Mnova software and Bruker BioSpin for AssureNMR software.

REFERENCES

1. Zost, S. J.; Gilchuk, P.; Case, J. B.; Binshtein, E.; Chen, R. E.; Nkolola, J. P.; Schäfer, A.; Reidy, J. X.; Trivette, A.; Nargi, R. S.; Sutton, R. E.; Suryadevara, N. E.; Martinez, D. R.; Williamson, L. E.; Chen, E. C.; Jones, T.; Day, S.; Myers, L.; Hassan, A. O.; Kafai, N. M.; Winkler, E. S.; Fox, J. M.; Shirihari, S.; Mueller, B. K.; Meiler, J.; Chandrashekar, A.; Mercado, N. B.; Steinhardt, J. J.; Ren, K.; Loo, Y.-M.; Kallewaard, N. L.; McCune, B. T.; Keeler, S. P.; Holtzman, M. J.; Barouch, D. H.; Gralinski, L. E.; Baric, R. S.; Thackray, L. B.; Diamond, M. S.; Carnahan, R. H.; Crowe, J. E. Potently Neutralizing
